Ritholtz Wealth Management Acquires 7,865 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Ritholtz Wealth Management increased its stake in Gilead by 6.2%, buying 7,865 shares to hold 135,318 shares valued at about $16.61 million.
• Analyst sentiment is largely positive: 24 Buys vs. 4 Holds, MarketBeat's average rating is a “Moderate Buy” with an average price target of $156.42 and several firms (Argus, JPMorgan) recently raised targets.
• Gilead beat Q results (EPS $1.86 vs. $1.83 est., revenue $7.93B vs. $7.68B), raised FY26 guidance and its quarterly dividend to $0.82, and is pursuing strategic moves including agreeing to acquire Tubulis for up to $5B and licensing KT‑200 (triggering a $45M milestone), while insiders have been net sellers and institutions own ~83.7% of the stock.

Ritholtz Wealth Management raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 135,318 shares of the biopharmaceutical company's stock after buying an additional 7,865 shares during the quarter. Ritholtz Wealth Management's holdings in Gilead Sciences were worth $16,609,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Corundum Trust Company INC bought a new stake in Gilead Sciences in the 3rd quarter valued at $26,000. Financial Consulate Inc. grew its stake in shares of Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 109 shares during the period. MTM Investment Management LLC grew its stake in shares of Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 176 shares during the period. BOCHK Asset Management Ltd bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $31,000. Finally, Millstone Evans Group LLC grew its stake in shares of Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 118 shares during the period. Institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on GILD. Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Argus upped their price objective on Gilead Sciences from $135.00 to $165.00 and gave the company a "buy" rating in a research note on Thursday, February 19th. Leerink Partners upped their price objective on Gilead Sciences from $146.00 to $148.00 and gave the company an "outperform" rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, February 11th. Finally, Citigroup reaffirmed a "buy" rating on shares of Gilead Sciences in a report on Friday, March 6th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $156.42.

Gilead Sciences Stock Down 2.2%

NASDAQ GILD opened at $139.03 on Friday. The firm has a market cap of $172.56 billion, a PE ratio of 20.54, a price-to-earnings-growth ratio of 1.89 and a beta of 0.39. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $157.29. The stock's 50 day simple moving average is $145.13 and its 200 day simple moving average is $130.36. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences's revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's payout ratio is currently 48.45%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Tubulis for up to $5 billion to expand its ADC oncology pipeline — a strategic bolt-on that supports Gilead’s shift into oncology and could drive longer‑term revenue growth. Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
• Positive Sentiment: Gilead exercised its option to license KT‑200 from Kymera, triggering a $45M milestone payment to Kymera and adding a first‑in‑class oral CDK2 degrader to its discovery-to-clinic pipeline — a validation of Gilead’s external innovation strategy. KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
• Positive Sentiment: Research partners and collaborations: expanded RWE and oncology R&D tie-ups (Tempus, Cartography) reinforce Gilead’s push to accelerate translational work and de‑risk discovery-stage assets. Tempus Announces Strategic Collaboration with Gilead
• Positive Sentiment: Sell-side lifts and bullish notes: Morgan Stanley raised its price target to $175 with an overweight rating (largest upside among today’s notes), and Truist also nudged up its target — these analyst actions can support buying interest. Price target raise at Morgan Stanley (Benzinga)
• Neutral Sentiment: Short‑interest data for April is effectively meaningless/zero in the report (shows 0 shares / NaN change), so it doesn’t provide directional insight into current positioning.
• Negative Sentiment: Cantor Fitzgerald cut its price target sharply to $115 (while oddly maintaining an overweight rating), introducing downside headline risk and signaling divergent analyst views on valuation. Cantor Fitzgerald Adjusts Price Target on Gilead Sciences
• Negative Sentiment: The AIDS Healthcare Foundation publicly criticized Gilead over its role in a Florida drugs situation — reputational and regulatory scrutiny can pressure sentiment and potentially elevate legal/regulatory risk. AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director owned 8,920 shares of the company's stock, valued at $1,101,620. This represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00. Following the sale, the insider directly owned 131,779 shares in the company, valued at approximately $19,006,485.17. This represents a 2.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 299,280 shares of company stock worth $42,820,550 in the last quarter. Insiders own 0.30% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.